Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01592370 · ClinicalTrials.gov registry record · Phase 1
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
A Phase 1 study of Multiple Myeloma and Hodgkin Lymphoma, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 320
- Enrollment target
- 20
- Study locations
NCT01592370: Completed Phase 1 study of Multiple Myeloma and Hodgkin Lymphoma, sponsored by Bristol-Myers Squibb.
NCT01592370 is a Phase 1 study of Multiple Myeloma and Hodgkin Lymphoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 320 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (41% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01592370, a Phase 1 study of Multiple Myeloma and Hodgkin Lymphoma, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 320 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the side effects of treatment of the combination of nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.
Primary Outcome
Number and percent of participants that experienced drug related Grade 3-4 AEs occurring up to 100 days after the last dose of study drug.
Conditions Studied
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Daratumumab
- BIOLOGICAL Ipilimumab
- DRUG Pomalidomide
- BIOLOGICAL Lirilumab
Study Locations (20)
California
- Local Institution - 0035 - Clovis
- Division Of Hematology & Oncology Ctr. For Health Sciences - Los Angeles
- Local Institution - 0012 - Los Angeles
Massachusetts
- Dana-Farber Cancer Institute - Boston
- Local Institution - 0009 - Boston
- Local Institution - 0015 - Boston
Maryland
- Local Institution - 0003 - Baltimore
- The Sidney Kimmel Comprehensive Cancer Center - Baltimore
Michigan
- Local Institution - 0011 - Ann Arbor
- University Of Michigan Health System - Ann Arbor
Minnesota
- Local Institution - 0002 - Rochester
- Mayo Clinic - Rochester
Colorado
- Local Institution - 0017 - Aurora
Connecticut
- Local Institution - 013 - New Haven
Florida
- Local Institution - 0023 - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2012-08-02 |
| Est. Completion | 2024-07-09 |
| Phase | Phase 1 |
What the finished NCT01592370 record still lists
NCT01592370 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (41% lower).
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Nivolumab is the first listed.
NCT01592370 names 20 study sites across 13 states, led by California, Massachusetts, Maryland.
Frequently Asked Questions
What is clinical trial NCT01592370 about?
NCT01592370 is a clinical study titled "An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma". The purpose of this study is to determine the side effects of treatment of the combination of nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.
What is the current status of trial NCT01592370?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 320 participants. The study started on 2012-08-02. Estimated completion is 2024-07-09.
What conditions does trial NCT01592370 study?
This clinical trial studies the following conditions: Multiple Myeloma, Hodgkin Lymphoma, Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT01592370?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Daratumumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), Pomalidomide (DRUG), Lirilumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01592370?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01592370 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01592370's enrollment target sits among peer trials
320 68th of 438 higher than 371 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI